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Abstract
The adipose tissue is an endocrine organ producing substances called adipocytokines that have different effects on
lipid metabolism, metabolic syndrome, and cardiovascular risk. Visfatin was recently described as an adipocytokine
with potentially important effects on glucose metabolism and atherosclerosis. Visfatin has been linked to several
inflammatory conditions, beta cell function, and cardiovascular disease. The growing number of publications on the
subject shall bring further evidence about this adipocytokine. Its findings may contribute in the identification of
higher risk individuals for diabetes and cardiovascular disease with a better comprehension about the complex
intercorrelation between adiposity, glucose metabolism and vascular disease.
Introduction
The ongoing global epidemic of atherosclerotic disease
is propelled by a concurrent rise in the prevalence of
obesity, insulin resistance, and type 2 diabetes (T2DM).
In this setting, the coexistence of several cardiovascular
risk factors aggregating around the metabolic syndrome
(MS), such as hyperglycemia, hypertension, dyslipidemia
and visceral obesity, is well-known [1]. The pathophysio-
logical relationship between cardiovascular disease and
these risk factors is of great importance due to their
high morbidity and mortality as well as impact on
healthcare costs [2]. Therefore, the link between visceral
adiposity and insulin resistance, endothelial dysfunction,
and subsequent atherosclerosis has been extensively
studied.
Adipose tissue is a known endocrine organ secreting
several soluble factors, known as adipocytokines or adi-
pokines, some of these being adiponectin, leptin, resistin
and, more recently, visfatin. They can partly explain the
link between obesity, insulin resistance, beta-cell dys-
function, endothelial dysfunction, and atherosclerosis
[3]. Other known products of adipocytes are free fatty-
acids, tumor necrosis factor (TNF)-alpha, interleukin
(IL)-6, IL-1, Monocyte chemoattractant protein (MCP)1,
coagulation mediators such as platelet-activator inhibitor
(PAI)-1, and complement components [1].
Atherosclerosis is a complex inflammatory disease,
involving many physiological mechanisms, in which
immunologic, metabolic, genetic, and environmental fac-
tors interact. The endothelium plays a pivotal role in
these interactions, through disequilibrium in regulation
of vascular tonus (endothelium-dependent relaxation),
platelet aggregation, coagulation, and fibrinolysis [4].
Risk factors for this condition have been continuously
identified.
Adipocytokines may have a role in each one of these
processes, explaining at least in part the association
between obesity, insulin resistance, diabetes, and cardio-
vascular disease.
Visfatin
Visfatin is an adipokine identified in 2004 [5] and thus
named for the suggestion that it would be predomi-
nantly produced and secreted in visceral fat. Visfatin is
highly preserved across animal evolution. It has a mole-
cular weight of 52 KDa and its gene encodes 491 ami-
noacids. It is identical to pre-B cell colony-enhancing
factor (PBEF), described in 1994 as a cytokine produced
by lymphocytes, acting on lymphocyte maturation and
inflammatory regulation. Visfatin was also soon recog-
nized as the formerly described Nicotinamide phosphor-
ibosyltransferase (Nampt), the limiting enzyme in
nicotinamide adenine dinucleotide (NAD) biosynthesis.
In addition to being produced in human leukocytes and
adipose tissue, visfatin is also expressed in human and
animal hepatocytes and muscles [6,7] and in animal
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adipocytes, kidney and heart [8-10]. Visfatin was found
to be released predominantly from macrophages rather
than from adipocytes in visceral adipose tissue. In this
regard, there is sufficient evidence to consider that visfa-
tin is expressed by the macrophages infiltrating adipose
tissue and is produced in response to inflammatory sig-
nals [11,12]. It is now believed that visfatin actions can
be endocrine, paracrine, and autocrine as well. These
autocrine effects of visfatin may play an important role
in regulating insulin sensitivity in the liver [9].
Fukuhara et al. investigated genes having diverse pat-
terns of expression in subcutaneous and visceral fat
from two human subjects, identifying one gene with
this feature [5]. Sequencing revealed this gene to cor-
respond to PBEF. Increased visfatin expression and
secretion was found during cell differentiation of cul-
tured adipocytes. Moreover, studying 101 humans,
strong correlation between visceral fat estimated by
computed tomography (CT) and visfatin plasma levels
was found, as well as a weak correlation between visfa-
tin levels and subcutaneous fat. Furthermore, an
increased visceral fat expression of visfatin was demon-
strated after weight gain in obese diabetic mice. In
these animals, acute administration of recombinant vis-
fatin decreased plasma glucose in a dose-dependent
fashion, in both insulin-resistant and insulin-deficient
animals. Chronic increase of visfatin expression
obtained by viral transfection has also decreased glu-
cose in both animal models. A homozygous knockout
model for the visfatin gene has been attempted, but it
was incompatible with life, fetal death occurring in the
initial phase of embryogenesis. However, heterozygous
animals showed plasma levels of visfatin two-thirds of
those seen in wild-type animals, associated to blood
glucose slightly higher in fasting, post-prandial state,
and after an oral glucose load. In addition, the study
has demonstrated insulin-mimetic effects of visfatin
such as: increased glucose uptake in adipocytes and
myocytes, suppression of hepatic glucose release, sti-
mulated triglyceride accumulation, and increase in its
synthesis in pre-adipocytes.
Further on, the authors investigated the intracellular
signaling of visfatin and suggested it to tyrosine-phos-
phorylate the insulin receptor in hepatocytes, myocytes,
and adipocytes. Competitive inhibition testing showed
that both molecules do not compete for the insulin
receptor, raising the hypothesis that visfatin could have
a binding site different from that of insulin. Actually,
recombinant receptors with structural changes decreas-
ing affinity for insulin didn’t change visfatin binding.
This study has opened a broad perspective for the role
of visfatin in mechanisms of glucose control. Although
its insulin-mimetic effects have been questioned, gener-
ating a retraction by the author in 2007 [13], numerous
subsequent studies demonstrated visfatin to bear impor-
tant metabolic effects as discussed below.
General actions of Visfatin and correlations with
medical conditions
Subsequent publications have reported various effects
and correlations between visfatin plasma levels with
various medical conditions (Table 1). It possesses anti-
apoptotic effects on neutrophils in both animal and clin-
ical models of sepsis [14]. It is also increased in acute
pulmonary lesion, being useful as a marker of this con-
dition [15]. Visfatin is also diminished in patients with
steatohepatitis when compared to pure steatosis [16].
However, increased visfatin levels correlated positively
with portal inflammation [17]. These observations could
suggest an association of visfatin with inflammation.
Negative correlation of visfatin with creatinine clearance
and positive correlation with urinary albumin excretion
has been demonstrated, suggesting visfatin circulating
levels to be influenced by renal function [18]. An inhibi-
tor of visfatin (FK866) is being tested as a potential anti-
tumor agent due to NAD depletion leading to apoptosis
on highly metabolically active cells [19].
The relationship of visfatin with visceral fat has been
questioned. Relationship of plasma visfatin levels was
seen with body mass index (BMI) and percentage of
body fat but not with abdominal circumference or
Table 1 Association between several medical conditions
and visfatin
Medical Condition Visfatin
Atherosclerosis Increased serum levels [10,31]
Increased expression in instable plaques [31]
Endothelial
dysfunction
Increased serum levels [18]
Cardioprotection Reduces infarct area [36]
Metabolic Syndrome Controversial, Increased serum levels [34]
Adiponectin Controversial [18,27]
Hepatic Fat Disease Diminished serum levels in steatohepatitis [16]
Increased serum levels with progressive portal
inflammation [17]
Tumoral replication Visfatin antagonist being tested [19]
Acute lung injury Increased serum levels [15]
Renal insufficiency Increased serum levels [18]
Beta cell function
impairment
Increased serum levels [10,22,23,28,29]
Insulin resistance No correlation [20,22,23]
Insulin-mimetic effect Controversial, no effect [5,10,15-20,22-24,27-29]
Diabetes Controversial [18,23,27,28]
Obesity Increased serum levels [20,22]
Visceral Fat Controversial, no correlation [5,15-20,27]
Vascular smooth
muscle
Promotes inflammation [32]
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visceral fat estimated by CT [20]. Chang et al. did not
find different expression of visfatin between visceral and
subcutaneous adipose tissue in 53 Taiwanese adults
[21]. Nevertheless, there is strong evidence that visfatin
increases with obesity as demonstrated in a prospective
cohort study, in which visfatin levels were augmented in
morbidly obese subjects compared to normal-weight
individuals. Visfatin normalized after 6 months of baria-
tric surgery and consequent weight loss [22]. Altogether
current evidence does not support the notion that visfa-
tin is predominantly expressed in visceral fat [21].
Visfatin in glucose metabolism
After the study by Fukuhara suggested a role of visfatin
on glucose metabolism, others have investigated its rela-
tionship with T2DM, insulin secretion and sensitivity,
and also with other adipokines such as adiponectin.
Revollo et al. showed that visfatin is an essential
enzyme in NAD production (Nampt). It exists both in
intra and extracellular environments. Mice heterozygous
for mutations in the visfatin gene have glucose intoler-
ance mainly due to insulin secretion deficiency. This
insulin secretion defect can be corrected by administer-
ing nicotinamide mononucleotide (NMN), the product
of visfatin on NAD biosynthesis. Since the pancreas has
very low levels of intracellular visfatin, the author sug-
gests that maintenance of high NMN circulating levels
by extracellular visfatin would be critical for normal
beta-cell function [10]. Skop et al. investigated glucose
uptake in animal hepatocytes with diminished visfatin
expression. They found significantly reduced NAD bio-
synthesis and significantly decreased incremental glucose
uptake after stimulation with insulin when compared to
control hepatocytes with normal expression of visfatin
[9]. A negative correlation of visfatin levels with beta-
cell function was demonstrated by studying acute insulin
secretion assessed by an intravenous glucose tolerance
test [23]. Furthermore, continuous glucose infusion in
humans acutely increases visfatin levels. This effect is
suppressed by insulin or somatostatin infusion [24].
Brown and co-authors demonstrated that incubation
with visfatin into mouse pancreatic beta-cells caused sig-
nificant changes in the mRNA expression of several key
diabetes-related genes, including marked up-regulation
of hepatocyte nuclear factor 1 homeobox B (HNF1B)
among others. Visfatin also caused a significant 46%
increase in insulin secretion compared to control at low
glucose, and this increase was blocked by co-incubation
with the specific visfatin inhibitor FK866. Both visfatin
and NMN induced activation of insulin receptor and
extracellular signal-regulated kinase (ERK)1/2, with vis-
fatin-induced activation of insulin receptor and ERK1/2
being inhibited by FK866. The authors suggested that
visfatin can significantly regulate insulin secretion,
insulin receptor phosphorylation, and expression of a
number of genes associated with beta-cell function in
mice [25].
Visfatin levels were also investigated in some popula-
tion based studies. Chen et al., investigating visfatin
levels in a Chinese population, found a positive associa-
tion between visfatin and the presence of T2DM, even
after adjustment for BMI, age, sex, smoking status,
blood pressure, and lipid profile [26]. Dogru et al.,
studying visfatin levels in 40 subjects with newly diag-
nosed diabetes or glucose intolerance, found that visfatin
levels were higher in the diabetic patients when com-
pared to controls, but not when compared to glucose
intolerant patients (pre-diabetes)[27]. Patients with both
long duration type 1 diabetes (T1DM) and T2DM had
higher visfatin levels compared to non-diabetic controls
or recently diagnosed diabetic individuals. In T2DM,
visfatin levels were partly associated to higher glycated
hemoglobin levels (A1C) [23]. Nevertheless, Takebayashi
found no correlation between diabetes and visfatin [18],
while another study, demonstrated decreased visfatin in
patients with T1DM and inverse relationship between
A1C and visfatin levels [28].
The relationship between visfatin levels and insulin
resistance surrogates was also investigated. However, it
was not possible to demonstrate correlation of visfatin
with HOMA-IR [20,23]. HOMA-IR also did not show
correlation with visfatin expression on visceral adipose
tissue but was positively associated with visfatin expres-
sion in subcutaneous adipocytes [21]. Furthermore,
administration of the insulin sensitizer pioglitazone for 3
weeks didn’t affect plasma levels of visfatin in humans
with recently diagnosed T2DM [29]. The same drug
administered for 12 weeks did not change visfatin levels
either [18]. This is not, apparently, a general effect of
thiazolidinediones, since rosiglitazone administered for 3
weeks increased visfatin levels in normoglycemic indivi-
duals [30].
Current data suggests that visfatin is important to nor-
mal insulin secretion, but its relationship with diabetes
risk and progression is still a matter of debate. Thus,
visfatin may be a compensatory mechanism or part of
the pathophysiology of diabetes.
Cardiovascular disease and visfatin
Oxidized LDL was verified to increase visfatin expres-
sion in cultured monocytes. Moreover, visfatin increased
the expression of molecules that degrade extracellular
matrix causing plaque instability. This later effect was
abolished after adding an inhibitor of insulin receptor
signaling [31].
Visfatin expression is increased in unstable coronary
plaques and symptomatic carotid lesions in humans.
Patients undergoing carotid endarterectomy and
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presenting ischemic symptoms 6 months prior to eva-
luation had higher visfatin expression than asympto-
matic individuals. The same finding has been replicated
in patients with unstable angina compared to those with
stable angina. Immunohistochemical analysis of the pla-
ques revealed higher concentration of visfatin in their
lipid nucleuses compared to stable plaques. The same
study showed that balloon angioplasty, acutely injuring
the plaques, caused visfatin levels to peak 4 hours after
the procedure, receding back to basal levels after 24
hours. Another study found a negative correlation
between visfatin and endothelial function evaluated
through flow-mediated or nitroglycerin-mediated dila-
tion [18]. Visfatin can promote vascular smooth muscle
inflammation, being associated with a potential role in
vascular dysfunction and inflammation associated with
some metabolic disorders [32].
Increased visfatin levels are associated to coronary
artery disease (CAD) and acute coronary syndromes
even after correction for classic cardiovascular risk fac-
tors such as cholesterol, smoking, hypertension, dia-
betes, and obesity [33]. A positive association between
visfatin and MS was noted, mainly among individuals
with carotid atherosclerosis. Indeed, visfatin was an
independent risk factor for augmented carotid intimal-
media thickness [34]. In this regard, it is well established
that acute ischemic stroke is another possible conse-
quence of atherosclerosis. Recently, higher visfatin levels
were found in Chinese individuals with stroke, suggest-
ing a possible role in this vascular disease [35].
A cardioprotective effect of visfatin was also suggested
in an animal model of non-atherosclerotic ischemia and
reperfusion [36]. Visfatin administered at the moment of
reperfusion diminished the size of the infarcted area.
This effect was mediated by the inhibition of the mito-
chondrial permeability transition pore (mPTP) opening,
a non-specific mitochondrial channel, its opening in the
first few minutes of myocardial reperfusion being a criti-
cal determinant of cardiomyocyte death. The authors
emphasize that this was an acute effect and chronically
elevated levels of visfatin may yield different results.
Genetic studies
The visfatin/PBEF gene consists of 11 exons and 10
introns spanning 34.7-kb and is located on chromosome
7q22.2. Few studies of polymorphic markers in the visfa-
tin gene have been reported to date. Bottcher et al. [37]
did not find any association with either T2DM, in a
cohort of 503 diabetic subjects and 476 healthy controls,
or with T2DM-related traits in 626 non-diabetic sub-
jects from Germany. However, they found an association
between the -948 G > T single-nucleotide polymorphism
(SNP) and fasting insulin levels in non-diabetic subjects
(p < 0.05). The ratio of visceral/subcutaneous visfatin
mRNA expression was associated with all three genetic
polymorphisms studied (rs9770242, -948G > T,
rs4730153).
To investigate the role of visfatin gene variants in obe-
sity-related phenotypes, Bailey et al. [38] genotyped a
total of 13 SNPs in the promoter region of the gene in
918 participants from 208 families evaluated in the Que-
bec Family Study. A significant association was found
between two SNPs (rs9770242 and rs1319501) and fast-
ing insulin levels (p = 0.002). These SNPs were also
associated with fasting glucose (p = 0.02). Furthermore,
they found that a more distal SNP (rs7789066) was sig-
nificantly associated with the apolipoprotein B compo-
nent of VLDL (p = 0.012).
Zhang et al. [39] studied a group of 814 white patients
from the USA and a group of non-diabetic controls (n =
320). They found a significant association between -948C
> A and T2DM (p = 0.021). In a non-diabetic population
(n = 630), the same -948C allele that conferred increased
risk of T2DM was significantly associated with higher
plasma levels of fibrinogen and C-reactive protein (p =
0.0022 and 0.0038, respectively). However, no significant
associations were observed with BMI, waist circumfer-
ence, serum glucose levels, or fasting insulin levels. They
suggested that the visfatin gene may play a role in deter-
mining T2DM susceptibility, possibly by modulating
chronic, low-grade inflammatory responses.
Korner et al. [40] studied 731 schoolchildren and an
independent cohort of 167 obese children from Ger-
many. They genotyped 3 SNPs (rs9770242, -948G > T,
rs4730153). The authors did not find association of any
of the 3 polymorphisms or their haplotypes with BMI,
waist-to-hip ratio, glucose, insulin, or lipid levels. How-
ever, the -948G variant was associated with significantly
higher diastolic blood pressure in obese children (p <
0.05 after adjusting for age, sex, pubertal stage, and
height).
Blakemore et al. [41] studied 1,709 severely obese sub-
jects together with 2,367 T2DM individuals and 2,850
controls. For quantitative trait analysis, an additional
2,362 subjects were typed for rs10487818 from a general
population sample. This rare SNP, rs10487818, located
in intron 4, was associated with protective effect against
severe obesity. This is one of the first rare SNPs shown
to be protective against a common polygenic disease
like obesity and provides further evidence that rare
alleles of strong effect can contribute to this kind of
complex diseases.
More recently, Yan et al. [42] suggested that Visfatin
-1535C > T polymorphism might be associated with
reduced risk of CAD in a Chinese population. There
was a significant association between Visfatin -1535C >
T polymorphism and triglyceride levels in both CAD
patients and controls (p = 0.003). In non diabetic
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Japanese subjects, Tokunaga et al. [43] found that the
-1535T/T genotype modulates lipid levels promoting
lower serum triglyceride levels and higher HDL-choles-
terol levels. In this investigation, reporter gene assay of
3T3-L1 adipocytes revealed that the promoter activity of
-1535T and -1535C was similar, suggesting that the
observed association may reflect linkage disequilibrium
between -1535T > C and other causative variations of
the visfatin gene.
Taken together, these studies suggest that genetic var-
iants in the Visfatin gene can be associated with some
phenotypes related to glucose, lipids, and other meta-
bolic and vascular traits. Further studies in other popu-
lations must be carried out to better clarify these points.
Conclusion and perspectives
Visfatin is is an adipokine involved in inflammatory phe-
nomena, atherosclerosis, and possibly in insulin secre-
tion. Its physiology has begun to be described but its
role on diabetes and CAD pathophysiology is still
controversial.
New studies may define the possible role of visfatin in
the mechanisms of glycemic control, vascular function
and atherosclerotic process. These findings may contri-
bute in the identification of higher risk individuals as
well as lead to new therapeutic approaches. Genetic stu-
dies about the visfatin gene and its variations will also
contribute to the elucidation of these phenomena.
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